Expression of Human Epidermal Growth Factor Receptor (Her 2/neu) and Proliferative Marker Ki-67: Association with Clinicopathological Parameters in Gallbladder Carcinoma

  • Published : 2016.08.01


Purpose: To evaluate the expression of Her2/neu and Ki-67 in benign and malignant gallbladder lesions, and to establish correlations with clinico-pathologic parameters. Materials and Methods: A retrospective analysis was conducted on formalin fixed paraffin embedded (FFPE) benign (n=25) and malignant gallbladder (n=25) tissue samples. Hematoxylin and eosin stained slides of each case were reviewed for: type of malignancy (whether adenocarcinoma, squamous cell carcinoma, or any other type), grade (well, moderate, and poor), depth of invasion, pre-neoplastic changes in adjacent mucosal epithelium like metaplasia and dysplasia. Immunohistochemistry for Her 2 neu and Ki-67 was performed and data analysis was conducted using SPSS 17 software. Chi-square test was used to compare categorical/dichotomous variables. P value of ${\leq}0.05$ was considered significant. Results: The difference of Her 2 neu expression and Ki67 index between benign and malignant groups was found to be statistically significant. Her2/neu positivity did not have any significant correlation with various clinicopathological parameters other than liver involvement. 5 cases of gallbladder cancer showed both Her2/neu and Ki67 positivity. Ten cases were Ki67 positive but Her2/neu negative while one case was Her2/neu positive but Ki67 negative. Conclusions: The present study demonstrated overexpression of Her2/neu and Ki67 in gallbladder cancer. A trend of decreasing Her2/neu expression with increasing grade of tumor was observed. Furthermore, greater Ki67 positivity was found in cases with lymph node metastasis and distant metastasis. Future studies with a larger number of patients will be required to precisely define the correlation of Her2/neu expression and Ki67 positivity with clinicopathological parameters. The results however are encouraging and suggest evaluation of Her2/neu as a candidate for targeted therapy.


Supported by : Indian Council of Medical Research


  1. Artico M, Bronzetti E, Alicino V, et al (2010). Human gallbladder carcinoma: Role of neutrophins, MIB-1, CD34 and CA15-3. Eur J Histo, 54, 10.
  2. Barreto SG, Dutt A, Chaudhary A (2014). A genetic model for gallbladder carcinogenesis and its dissemination. Ann Oncol, 25, 1086-97.
  3. Bizama C, Garcia P, Espinoza JA, et al (2015). Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev, 41, 222-34.
  4. Chaube A, Tewari M, Garbyal RS, et al (2006). Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients. BMC Cancer, 6, 126.
  5. Chua TC, Merrett ND (2012). Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int J Cancer, 130, 2845-56.
  6. Dhir V, Mohandas KM (1999). Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol, 18, 24-8.
  7. Doval DC, Azam S, Sinha R, et al (2014). Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma. J Carcinog, 13, 10.
  8. Ghosh Y, Thakurdas B (2015). Carcinoma gallbladder: A review of literature. Int J Scien Study, 2, 98-103.
  9. Goldin RD, Roa JC (2009). Gallbladder cancer: a morphological and molecular update. Histopathol, 55, 218-29.
  10. Grau LAH, Badia JM, Salvador CA, et al (2004). Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen as prognostic markers. HPB (Oxford), 6, 174-80.
  11. Harder J, Waiz O, Otto F (2009). EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol, 15, 4511-7.
  12. Hui AM, Shi YZ, Li X, et al (2002). Proliferative marker Ki-67 in gallbladder carcinomas: high expression level predicts early recurrence after surgical resection. Cancer Lett, 176, 191-8.
  13. Hundal R, Shaffer EA (2014). Gallbladder Cancer: epidemiology and outcome. Clin Epidemiol, 6, 99-109.
  14. Javle M, Churi C, Kang HSC, et al (2015). HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol, 8, 58.
  15. Kai K, Masuda M, Ide T, et al (2013). Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor. Mol Clin Oncol, 1, 633-8.
  16. Kapoor VK, McMichael AJ (2003). Gallbladder cancer: an ‘Indian’ disease. Natl Med J India, 16, 209-13.
  17. Kawamoto T, Krishnamurthy S, Tarco E, et al (2007). HER receptor family: novel candidate for targeted therapy for gall bladder and extrahepatic bile duct cancer. Gastrointest Cancer Res, 1, 221-7.
  18. Kim YW, Huh SH, Park YK (2001). Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep, 8, 1127-32.
  19. Kumari N, Kapoor VK, Krishnani N, et al (2012). Role of C-erbB2 expression in gallbladder cancer. Indian J Pathol Microbiol, 55, 75-9.
  20. Matsuyama S, Kitajima Y, Sumi K, et al (2004). Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. Oncol Rep, 11, 815-9.
  21. Mitri Z, Constantine T, O'Regan (2012). The HER2 receptor in breast cancer: pathophysiology: clinical use, and new advances in therapy. Chemother Res Pract, 2012, 743193.
  22. Nakazawa K, Dobashi Y, Suzuki S, et al (2005). Amplification and overexpression of C-erbB2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol, 206, 356-65.
  23. Puhalla H, Wrba F, Kandioler D (2007). Expression of p21(Waf1/ Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res, 27, 1679-84.
  24. Rakic M, Patrlj L, Kopljar M, et al (2014). Gallbladder cancer. Hepatobiliary Surg Nutr, 3, 221-6.
  25. Roa EI, Elorza DX, Lantadilla HS, et al (2009). Immunohistochemical expression of Ki67 as a marker of proliferation in gallbladder mucosa samples with or without cancer. Rev Med Chil, 137, 881-7.
  26. Roa I, de Toro G, Schalper K, et al (2014). Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointestinal Cancer Res, 7, 42-8.
  27. Shrestha ML, Miyake H, Kikutsuji T, et al (1998). Prognostic significance of Ki67 and p53 antigen expression in carcinomas of bile duct and gallbladder. J med Invest, 45, 95-102.
  28. Toledo C, Matus CE, Barraza X, et al (2012). Expression of HER2 and bradykinin B1 receptors in precursor lesions of gallbladder carcinoma. World J Gastroenterol, 18, 1208-15.